BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer Read more →
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win Read more →
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test Read more →
